Daewon Pharmaceutical Co., Ltd.
KRX:003220.KS
15690 (KRW) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 526,952.045 | 478,884.656 | 354,176.435 | 308,501.016 | 317,827.567 | 286,652.511 | 265,462.478 | 240,722.374 | 216,187.083 | 181,984.511 | 158,878.874 | 138,168.465 | 138,874.713 | 144,696.109 | 115,930.546 | 90,659.34 | 74,356.701 |
Cost of Revenue
| 272,719.77 | 240,942.657 | 177,708.542 | 142,563.728 | 137,672.153 | 121,164.449 | 113,418.359 | 103,208.222 | 99,036.483 | 81,682.714 | 73,865.105 | 65,622.273 | 61,651.344 | 58,336.294 | 44,437.843 | 30,846.069 | 24,177.677 |
Gross Profit
| 254,232.275 | 237,941.999 | 176,467.894 | 165,937.288 | 180,155.413 | 165,488.062 | 152,044.119 | 137,514.152 | 117,150.599 | 100,301.797 | 85,013.769 | 72,546.192 | 77,223.368 | 86,359.815 | 71,492.703 | 59,813.271 | 50,179.024 |
Gross Profit Ratio
| 0.482 | 0.497 | 0.498 | 0.538 | 0.567 | 0.577 | 0.573 | 0.571 | 0.542 | 0.551 | 0.535 | 0.525 | 0.556 | 0.597 | 0.617 | 0.66 | 0.675 |
Reseach & Development Expenses
| 18,206.744 | 19,473.358 | 24,563.017 | 13,477.506 | 10,243.523 | 9,275.45 | 6,762.205 | 6,634.021 | 6,436.143 | 10,037.95 | 5,753.943 | 4,785.487 | 5,680.716 | 2,207.634 | 1,993.771 | 1,524.058 | 1,918.338 |
General & Administrative Expenses
| 31,430.08 | 41,343.234 | 27,671.402 | 20,329.274 | 21,737.304 | 20,901.173 | 22,097.552 | 19,123.58 | 17,267.091 | 13,246.749 | 11,516.108 | 9,511.838 | 9,132.548 | 9,101.087 | 9,181.321 | 7,839.732 | 6,670.153 |
Selling & Marketing Expenses
| 72,005.289 | 58,271.777 | 50,858.397 | 45,125.121 | 46,656.487 | 43,620.843 | 40,059.082 | 26,913.994 | 22,125.388 | 15,495.34 | 12,415.884 | 9,546.842 | 13,697.837 | 21,610.156 | 18,149.187 | 16,288.656 | 12,720.985 |
SG&A
| 203,792.732 | 99,615.011 | 78,529.799 | 65,454.395 | 68,393.791 | 64,522.016 | 62,156.634 | 46,037.574 | 39,392.479 | 28,742.089 | 23,931.992 | 19,058.681 | 22,830.385 | 30,711.243 | 27,330.508 | 24,128.388 | 19,391.138 |
Other Expenses
| 1,111.626 | 95,320.612 | 78,512.189 | 62,906.494 | 66,410.968 | 1,288.033 | -578.289 | -109.649 | -52.028 | 2,778.819 | 161.349 | 207.31 | -185.696 | -1,492.951 | -1,187.219 | -807.812 | -699.11 |
Operating Expenses
| 221,999.477 | 194,935.623 | 157,041.988 | 141,838.395 | 145,048.282 | 134,742.479 | 126,749.664 | 108,366.544 | 94,065.57 | 82,495.653 | 69,469.426 | 59,048.09 | 63,837.515 | 66,290.315 | 57,432.324 | 48,252.367 | 40,629.982 |
Operating Income
| 32,232.799 | 43,006.377 | 19,425.905 | 24,098.893 | 35,107.13 | 30,745.583 | 25,294.455 | 29,147.609 | 23,085.03 | 17,806.143 | 15,544.343 | 13,498.102 | 12,666.544 | 20,069.499 | 14,060.381 | 11,560.902 | 9,549.042 |
Operating Income Ratio
| 0.061 | 0.09 | 0.055 | 0.078 | 0.11 | 0.107 | 0.095 | 0.121 | 0.107 | 0.098 | 0.098 | 0.098 | 0.091 | 0.139 | 0.121 | 0.128 | 0.128 |
Total Other Income Expenses Net
| -6,912.026 | -4,284.356 | -2,289.936 | -457.391 | 265.111 | 464.271 | -1,769.572 | -1,396.198 | 161.951 | 3,318.193 | 57.854 | -942.888 | -856.786 | 130.607 | -1,710.23 | -1,782.311 | 124.693 |
Income Before Tax
| 25,320.773 | 38,722.02 | 17,135.969 | 23,641.503 | 35,372.24 | 31,209.854 | 23,524.883 | 27,751.409 | 23,246.981 | 21,124.336 | 15,602.197 | 12,555.214 | 12,529.067 | 20,200.107 | 12,350.149 | 9,778.593 | 9,673.735 |
Income Before Tax Ratio
| 0.048 | 0.081 | 0.048 | 0.077 | 0.111 | 0.109 | 0.089 | 0.115 | 0.108 | 0.116 | 0.098 | 0.091 | 0.09 | 0.14 | 0.107 | 0.108 | 0.13 |
Income Tax Expense
| 2,366.929 | 8,064.849 | 10,525.293 | 6,443.017 | 8,492.827 | 7,923.567 | 13,250.078 | 8,028.158 | 5,913.5 | 5,526.982 | 3,368.906 | 2,789.062 | 3,272.157 | 8,354.382 | 2,588.333 | 2,105.28 | 1,854.413 |
Net Income
| 23,916.931 | 31,944.351 | 6,988.826 | 17,640.389 | 27,288.954 | 23,744.482 | 10,742.011 | 20,241.973 | 17,694.917 | 15,728.543 | 12,320.945 | 9,614.764 | 9,436.354 | 11,845.725 | 9,761.816 | 7,673.313 | 7,819.323 |
Net Income Ratio
| 0.045 | 0.067 | 0.02 | 0.057 | 0.086 | 0.083 | 0.04 | 0.084 | 0.082 | 0.086 | 0.078 | 0.07 | 0.068 | 0.082 | 0.084 | 0.085 | 0.105 |
EPS
| 1,139.91 | 1,509.75 | 329.36 | 826.31 | 1,265.08 | 1,100.64 | 473.96 | 906.62 | 790.24 | 688.52 | 539.35 | 401.93 | 478.7 | 590.61 | 525.51 | 403.52 | 399.41 |
EPS Diluted
| 1,110.44 | 1,478.37 | 329.36 | 826.31 | 1,265.08 | 1,068.54 | 473.96 | 906.62 | 790.24 | 688.52 | 539.35 | 401.93 | 478.7 | 590.61 | 525.51 | 403.52 | 399.41 |
EBITDA
| 49,793.513 | 65,209.725 | 39,635.89 | 41,033.783 | 47,803.39 | 42,703.124 | 33,715.639 | 38,342.392 | 29,543.41 | 25,786.503 | 20,654.512 | 18,067.484 | 17,064.196 | 23,476.684 | 17,725.354 | 13,942.934 | 11,767.136 |
EBITDA Ratio
| 0.094 | 0.136 | 0.112 | 0.133 | 0.15 | 0.149 | 0.127 | 0.159 | 0.137 | 0.142 | 0.13 | 0.131 | 0.123 | 0.162 | 0.153 | 0.154 | 0.158 |